中国医学创新
中國醫學創新
중국의학창신
Medical Innovation of China
2015年
26期
68-70,71
,共4页
肠易激综合征%痛泻宁颗粒%双歧杆菌乳杆菌三联活菌片(金双歧)%微生态制剂
腸易激綜閤徵%痛瀉寧顆粒%雙歧桿菌乳桿菌三聯活菌片(金雙歧)%微生態製劑
장역격종합정%통사저과립%쌍기간균유간균삼련활균편(금쌍기)%미생태제제
Irritable bowel syndrome%Tongxiening granule%Live combined bifidobacterium and lactobacillus tablets(Golden Bifid)%Probiotics
目的：观察痛泻宁颗粒与双歧杆菌乳杆菌三联活菌片（金双歧）联用治疗腹泻型肠易激综合征的疗效。方法：采用随机、平行对照研究方法，将75例符合入选标准的IBS-D患者分为A组（痛泻宁加金双歧试验组）及B组（单用痛泻宁组）、C组（单用金双歧组），每组各25例，对患者的腹痛、腹泻、总体症状进行评分，根据症状积分变化判断疗效。结果：治疗4周后三组患者治疗前后腹痛评分、腹泻评分和症状总评分比较差异均有统计学意义（P<0.01）；治疗结束时三组患者症状评分比较，A组与其他两组的腹痛评分、腹泻评分及症状总评分比较差异有统计学意义（P<0.01），B、C两组比较差异无统计学意义（P>0.05）。疗效比较， A组与B组、A组与C组间腹痛、腹泻症状疗效及总体疗效比较差异均有统计学意义（P<0.05），B组与C组间比较差异均无统计学意义（P>0.05）。结论：痛泻宁颗粒与金双歧联用治疗IBS-D可明显改善患者的核心症状，疗效更佳，无不良反应。
目的：觀察痛瀉寧顆粒與雙歧桿菌乳桿菌三聯活菌片（金雙歧）聯用治療腹瀉型腸易激綜閤徵的療效。方法：採用隨機、平行對照研究方法，將75例符閤入選標準的IBS-D患者分為A組（痛瀉寧加金雙歧試驗組）及B組（單用痛瀉寧組）、C組（單用金雙歧組），每組各25例，對患者的腹痛、腹瀉、總體癥狀進行評分，根據癥狀積分變化判斷療效。結果：治療4週後三組患者治療前後腹痛評分、腹瀉評分和癥狀總評分比較差異均有統計學意義（P<0.01）；治療結束時三組患者癥狀評分比較，A組與其他兩組的腹痛評分、腹瀉評分及癥狀總評分比較差異有統計學意義（P<0.01），B、C兩組比較差異無統計學意義（P>0.05）。療效比較， A組與B組、A組與C組間腹痛、腹瀉癥狀療效及總體療效比較差異均有統計學意義（P<0.05），B組與C組間比較差異均無統計學意義（P>0.05）。結論：痛瀉寧顆粒與金雙歧聯用治療IBS-D可明顯改善患者的覈心癥狀，療效更佳，無不良反應。
목적：관찰통사저과립여쌍기간균유간균삼련활균편（금쌍기）련용치료복사형장역격종합정적료효。방법：채용수궤、평행대조연구방법，장75례부합입선표준적IBS-D환자분위A조（통사저가금쌍기시험조）급B조（단용통사저조）、C조（단용금쌍기조），매조각25례，대환자적복통、복사、총체증상진행평분，근거증상적분변화판단료효。결과：치료4주후삼조환자치료전후복통평분、복사평분화증상총평분비교차이균유통계학의의（P<0.01）；치료결속시삼조환자증상평분비교，A조여기타량조적복통평분、복사평분급증상총평분비교차이유통계학의의（P<0.01），B、C량조비교차이무통계학의의（P>0.05）。료효비교， A조여B조、A조여C조간복통、복사증상료효급총체료효비교차이균유통계학의의（P<0.05），B조여C조간비교차이균무통계학의의（P>0.05）。결론：통사저과립여금쌍기련용치료IBS-D가명현개선환자적핵심증상，료효경가，무불량반응。
Objective:To observe the efficacy of combined Tongxiening granule and Golden Bifid for the treatment of patients with dominant-diarrhea irritable bowel syndrome.Method: Randomized and parallel-group study method was used, 75 IBS-D patients who met the inclusion criteria were divided into three groups: group A (combined Tongxiening granule and Golden bifid tablets study group), group B (Tongxiening granule alone control group) and group C (Golden bifid tablets alone control group), 25 cases in each group. The symptoms of abdominal pain, diarrhea and global symptom were scored. The efficacy was determined by the changes of symptom scores.Result:After treatment for 4 weeks, compared the abdominal pain scores, diarrhea symptoms scores and total symptoms scores of three groups before and after treatment, the differences were statistically significant(P<0.01).After treatment,compared the symptoms scores of three groups patients, group A had statistically significant differences with the other two groups(P<0.01), but had no statistical differences between the group B and C(P>0.05).Compared the effect of three groups, group A had statistically significant difference with the other two groups(P<0.05), but had no statistical differences between the group B and C (P>0.05).Conclusion:Adjunctive therapy of Tongxiening granule and Golden Bifid tablets for IBS-D obviously improve the core symptoms of patients, has a better curative effect and no adverse reaction.
